Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in NSCLC after platinum failure
NCT03616691Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Aug 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Primary endpoint: Disease Control Rate at 36 months. Status: unknown.
02
Drugs
atezolizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03616691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616691.